View Older Stories View More Recent Stories
-
Revolution Medicines, Inc. (RVMD) Misses Q4 EPS by 28c
-
Revolution Medicines (RVMD) spreader of April 80, June 50 and June 80 puts
-
Revolution (RVMD) PT Raised to $150 at Oppenheimer
-
Truist Securities keeps Revolution (RVMD) at Buy, 'believe that RVMD is well funded and doesn't need to do a deal'
-
Revolution Medicines stock falls after Merck reportedly ends acquisition pursuit
-
Merck ends acquisition talks with Revolution Medicines - WSJ
-
Revolution (RVMD) PT Raised to $170 at Stifel as Pipeline Has Unrecognized Value
-
Revolution (RVMD) PT Raised to $140 at RBC Capital
-
Revolution (RVMD) PT Raised to $160 at Guggenheim
-
Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'
-
RStifel on evolution Medicines (RVMD): 'RVMD's Hand is Looking Stronger Than Ever!'
-
Truist Securities Reiterates Buy Rating on Revolution (RVMD)
-
STAT reported Feuerstein: meeting with Revolution Medicines CEO cancelled
-
Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ
-
Revolution Medicines (RVMD) CEO Said to Cancel Upcoming Meetings Amid M&A Chatter
-
Revolution (RVMD) PT Raised to $109 at BofA Securities
-
After-hours movers: Rocket Companies, General Motors, Intel, and more
-
Merck Discussed $28B-$32B Price For Revolution Medicines - FT
-
Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT
-
Stifel Reiterates Buy Rating on Revolution (RVMD): Will Remain Independent
-
BofA top picks in biotech as sector heading for recovery in 2026
-
After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more
-
Abbvie: Not In Discussions With Revolution Medicines - Reuters
-
AbbVie in Advanced Talks to Buy Revolution Medicines - WSJ
-
Revolution Medicines (RVMD) halted on circuit breaker following takeover report
-
Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'
-
Erasca, Inc (ERAS) Pulls Back from 20+pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'
-
Here's the list of top biotech stocks to own for 2026
-
TD Cowen: 'Revolution (RVMD) Is Our 2026 Best Idea'
-
These stocks are latest additions to Mizuho's Top Picks list
-
Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 20c
-
RBC Capital Starts Revolution (RVMD) at Outperform
-
Revolution Medicines receives FDA orphan drug status for pancreatic cancer drug
-
Revolution Medicines reports elironrasib data for lung cancer patients
-
Mizuho Starts Revolution (RVMD) at Outperform
-
Revolution (RVMD) PT Raised to $80 at BofA Securities
-
Revolution (RVMD) PT Raised to $76 at Raymond James
-
Stifel Starts Revolution (RVMD) at Buy
-
Raymond James Assumes Revolution (RVMD) at Strong Buy, 'a prime takeout target'
-
Revolution (RVMD) PT Raised to $66 at Needham
-
Truist Securities Starts Revolution (RVMD) at Buy, PT $99
-
Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)
-
Piper Sandler Starts Revolution (RVMD) at Overweight
-
LifeSci Capital Starts Revolution (RVMD) at Outperform
-
Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 19c
-
Revolution Medicines publishes research on RAS G12D inhibitor in Science
-
Goldman Sachs Starts Revolution (RVMD) at Buy
-
Revolution Medicines partners with Iambic for AI drug discovery
-
H.C. Wainwright Reiterates Buy Rating on Revolution (RVMD)
-
Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
